Wells Fargo notes that on Monday, American Diabetes Association published its 2025 Standards of Care in Diabetes guidelines, which includes a new recommendation for CGM use in people with T2 diabetes, including those not on insulin. The choice of device should be made based on the individual’s circumstances, preferences, and needs, it said. The firm views this as a positive step forward toward coverage. Publicly traded companies in the space include Abbott (ABT) and Dexcom (DXCM).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Abbott price target raised to $149 from $143 at Barclays
- Reckitt and Abbott Shares Rally on Baby Formula Lawsuit Win
- Morning Movers: Apple dips, Amazon gains after earnings
- Abbott, Mead Johnson secure win in infant formula trial, Reuters reports